Portfolio
OPELCONAZOLE
Opelconazole has the potential to be useful in a variety of conditions where Aspergillus has been implicated, including invasive pulmonary aspergillosis, aspergilloma, chronic necrotizing pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, and severe asthma with fungal sensitization. Opelconazole is initially being investigated for the acute treatment of invasive pulmonary aspergillosis in patients who are not responding to standard-of-care antifungal treatment, with the potential to be used in additional acute and chronic Aspergillus-associated conditions, as both a treatment and prophylaxis. Opelconazole has received several FDA designations that may facilitate its expedited development and/or review, including an orphan drug designation, Fast Track designation, and qualified infectious disease product (QIDP) designation. It has also been granted orphan drug designation in the European Union.
OUR PRODUCT PIPELINE
Preclinical
Phase 1
Phase 2
Phase 3
Treatment of Invasive Pulmonary Aspergillosis
Preclinical
Phase 1
Phase 2
Phase 3
Prophylaxis of Pulmonary Aspergillosis
Preclinical
Phase 1
Phase 2
Phase 3
Chronic Pulmonary Disease
(e.g. ABPA, SAFS, CPA)
Preclinical
Phase 1
Phase 2
Phase 3
Dry Powder Inhaler
Preclinical
Phase 1
Phase 2
Phase 3
POTENTIAL PATIENT POPULATIONS†
Aspergillus is implicated in a number of acute and chronic conditions.
